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Abstract
Background
Trachoma, caused by Chlamydia trachomatis, remains the leading infectious cause of blind-
ness worldwide. Persistence and progression of the resulting clinical disease appears to be
an immunologically mediated process. Azithromycin, which is distributed at the community
level for trachoma control, has immunomodulatory properties. We investigated the impact of
one round of oral azithromycin on conjunctival immune responses, C. trachomatis infection
and clinical signs three- and six- months post treatment relative to three pre-treatment time-
points.
Methodology
A cohort of children aged 6 to 10 years were recruited from a trachoma endemic region of
northern Tanzania and were visited five times in a 12-month period. They were examined
for clinical signs of trachoma and conjunctival swabs were collected for laboratory analysis.
C. trachomatis infection was detected and the expression of 46 host genes was quantified
using quantitative PCR. All community members were offered azithromycin treatment
immediately after the six-month timepoint according to international guidelines.
Findings
The prevalence of C. trachomatis infection and inflammatory disease signs were signifi-
cantly reduced three- and six- months post-mass drug administration (MDA). C. trachomatis
infection was strongly associated with clinical signs at all five time-points. A profound anti-
inflammatory effect on conjunctival gene expression was observed 3 months post-MDA,
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however, gene expression had largely returned to pre-treatment levels of variation by 6
months. This effect was less marked, but still observed, after adjusting for C. trachomatis
infection and when the analysis was restricted to individuals who were free from both infec-
tion and clinical disease at all five time-points. Interestingly, a modest effect was also
observed in individuals who did not receive treatment.
Conclusion
Conjunctival inflammation is the major clinical risk factor for progressive scarring trachoma,
therefore, the reduction in inflammation associated with azithromycin treatment may be ben-
eficial in limiting the development of potentially blinding disease sequelae. Future work
should seek to determine whether this effect is mediated directly through inhibition of pro-
inflammatory intracellular signalling molecules, through reductions in concurrent, sub-clini-
cal infections, and/or through reduction of infection exposure.
Author summary
Trachoma, caused by conjunctival infection with Chlamydia trachomatis, remains the
leading infectious cause of blindness. Repeated infection during childhood can trigger
prolonged inflammation, which is the main risk factor for conjunctival scarring. Azithro-
mycin is distributed globally for trachoma control, however it is also widely reported to
have immunomodulatory properties. This report investigated the impact of one round of
oral azithromycin for trachoma control on conjunctival immune responses, clinical signs
and C. trachomatis infection in Tanzanian children. A large anti-inflammatory effect of
azithromycin on conjunctival gene expression was observed 3 months post-treatment,
however, gene expression patterns had mostly resumed to pre-treatment levels by 6
months. The effect was evident after adjusting for C. trachomatis infection and when anal-
ysis was restricted to uninfected individuals, however it was also observed to a lesser
extent in individuals that did not receive treatment. These findings suggest that azithro-
mycin may have a direct immunomodulatory effect on conjunctival gene expression but
that it may also reduce inflammation by reducing exposure to C. trachomatis and other
infections. This anti-inflammatory effect could have therapeutic potential in limiting the
development of disease sequelae, that goes beyond its effect on the clearance of ocular C.
trachomatis infection.
Introduction
Trachoma remains the leading infectious cause of blindness worldwide, with the greatest
burden in sub-Saharan Africa [1]. Trachomatous disease is initiated by repeated conjuncti-
val infection with Chlamydia trachomatis, which triggers prolonged inflammatory episodes
that contribute to the development of conjunctival scarring [2]. Infection and clinical signs
of active trachoma (follicular and papillary inflammation) are most frequently found in
younger children [3]. Conjunctival scarring gradually accumulates through childhood, ado-
lescence and into adult life. Eventually this results in the in-turning of the eyelid (entropion)
and eyelashes (trichiasis), abrasion of the eyelashes against the cornea, severe visual
impairment and blindness in later life. According to recent World Health Organisation
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(WHO) estimates, around 165.1 million people live in trachoma-endemic areas (of whom
89% are from WHO’s African region) [4] and 2.8 million have trichiasis [5]. The WHO
advocates the use of the SAFE Strategy for trachoma control: Surgery to correct trichiasis,
Antibiotics to treat C. trachomatis infection, Facial cleanliness and Environmental improve-
ments to suppress transmission [6].
Annual mass drug administration (MDA) with oral azithromycin for a minimum of 3 years
is recommended for communities where the initial prevalence of the clinical sign trachoma-
tous inflammation-follicular (TF) is�10% in children aged 1 to 9 years, with a recommended
coverage of 80% of the whole community [7]. In low-prevalence settings this usually leads to a
sustained reduction in C. trachomatis infection prevalence over time [8–11], however in highly
endemic areas infection can re-emerge shortly after MDA [12].
Inflammatory disease signs are reported to persist longer than infection at both the individ-
ual and population levels, resulting in the observation of clinical signs in the absence of infec-
tion [13–16]. The correlation between clinical signs and C. trachomatis infection in
communities prior to MDA is further reduced following treatment [14].
Previously we reported on the relationship between clinical signs, C. trachomatis infection
and the expression of 91 immuno-fibrogenic and cell marker genes at the baseline time-point
of a long-term cohort study of Tanzanian children [17]. We found an increase in transcripts
related to Th1 and NK cell activity in individuals with C. trachomatis infection and an increase
in matrix and fibrogenic factors in individuals with active disease in the absence of infection,
supporting the findings of several earlier studies [16, 18–24]. However, the changes of these
transcriptional responses in an untreated population and the changes that might occur follow-
ing MDA with azithromycin have not previously been investigated.
Azithromycin is a macrolide antibiotic which has anti-inflammatory and immunomodula-
tory properties via inhibition of the transcription factor Nuclear Factor Kappa-B [25]. Azithro-
mycin has been reported in vitro to suppress T-cell proliferation and activation and to reduce
the expression of mucins and pro-inflammatory cytokines [26–28]. As a result azithromycin is
found to be beneficial in the treatment of diseases characterised by pathological inflammation
[29]. Azithromycin therefore has the potential to exert broad anti-inflammatory effects on
conjunctival gene expression, independently of the clearance of C. trachomatis.
Here we investigate the changes in clinical signs of trachoma, C. trachomatis infection and
host immune responses in a cohort of Tanzanian children three- and six-months post azithro-
mycin MDA relative to three pre-treatment time-points. We also investigate the associations
between clinical signs, infection and immune responses before and after MDA. This investiga-
tion uses data from the first five time-points of a four-year longitudinal study, the baseline
findings of which have previously been reported [17].
Methods
Ethics statement
This study was reviewed and approved by the Ethics Committees of the Tanzania National
Institute for Medical Research, Kilimanjaro Christian Medical University College and the Lon-
don School of Hygiene & Tropical Medicine. The study adhered to the tenets of the Declara-
tion of Helsinki. A field worker explained the nature of the study in detail in either Kiswahili
or Maasai. Prior to enrolment of a child into this study, their parent or guardian provided writ-
ten informed consent, on a consent form in Kiswahili, which was witnessed by a third person.
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Study design and population
This study was conducted in three adjacent trachoma endemic communities in Kilimanjaro
and Arusha regions, Northern Tanzania. In January 2012 we recruited a cohort of children
aged 6–10 years from these communities to study the pathogenesis of trachomatous conjuncti-
val scarring. The cohort has subsequently been followed-up every three months for four years.
All children aged 6–10 years, who were normally resident in the three villages, were eligible for
inclusion. We chose this restricted age group as we considered that they were more likely to
show evidence of incident or progressive conjunctival scarring during the four years of the
study. The investigation presented in this paper is nested within this overall longitudinal study
and uses data from the first five time-points only. The objectives of this nested investigation
were to examine changes in C. trachomatis infection, clinical signs of trachoma and host
immune responses, and the associations between them, three- and six-months post treatment
relative to three pre-treatment time-points.
The study population and participant recruitment process are described in more detail in
the report of baseline (time-point 1) findings [17]. In brief, these villages are relatively remote,
geographically neighbours and have similar patterns of life and traditions. This area is predom-
inately inhabited by people of the Maasai ethnic group. Pastoral activities are the main occupa-
tion. The area is dry for much of the year, except for the rainy season (February to May).
Water supply is therefore limited, and largely depends on a long-distance water pipe scheme
from Mount Kilimanjaro. Family units are organised in Boma, with living huts arranged in a
circle around a central animal enclosure, which is often characterised by a high density of flies.
Clinical assessments and sample collection
We visited the cohort of children every three months at their homes or schools. An experi-
enced ophthalmic nurse examined their left eye for clinical signs of trachoma using x2.5 loupes
and a bright torch. Signs were graded using the 1981 WHO ‘FPC’ detailed grading system
[30]. This sub-divides the features into several four-point severity scales: follicles (F), papillary
inflammation (P) and conjunctival scarring (C). This system corresponds to the WHO Simpli-
fied Trachoma Grading System in the following way: Trachomatous inflammation-Follicular
(TF) is equivalent to F2/F3 and Trachomatous inflammation-Intense (TI) is equivalent to P3
[31]. Where we refer to “Active Trachoma”, we follow the widely used definition of TF (F2/3)
and/or TI (P3). However for the purpose of this study, we also consider that both P2 and P3
represent clinically significant papillary inflammation, and refer to this as “TP” [18]. High res-
olution photographs (Nikon D90 camera with 105mm Macro lens) were taken of the exam-
ined eye for independent grading.
The conjunctiva of the left eye was anaesthetised with a drop of preservative-free proxyme-
tacaine hydrochloride 0.5% w/v (Minims, Chauvin Pharmaceuticals Ltd, Surrey, UK). Two
conjunctival swab samples (Dacron polyester, Puritan Medical Products Company, Maine,
USA) were collected for C. trachomatis detection and gene expression analysis. The swabs
were passed across the upper tarsal conjunctiva four times, with a quarter turn between each
pass. The first swab was placed directly into a tube containing RNAlater solution (Thermo
Fisher Scientific, Massachusetts, USA) and the second into a dry tube. The samples were
placed into a cool box. Later the same day the dry swab samples were stored directly at -80˚C
and the RNAlater samples kept at 4–8˚C overnight and then stored at -80˚C.
Trachoma control measures
The SAFE Strategy is being implemented in this region of Tanzania. Community members
who had trachomatous trichiasis were offered free surgery in the local health facility.
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Azithromycin MDA was distributed to the members of the three villages by our field team
under the auspices of the Tanzanian National NTD Control Programme in the Ministry of
Health and with supervision by district eye coordinators. Azithromycin, donated to the
National NTD Control Programme by Pfizer through the International Trachoma Initiative,
was offered to all community members over the age of 6 months. Single-dose azithromycin
MDA (1g for adults and 20mg/kg for children) was distributed annually for three years. For
infants under six months, tetracycline eye ointment was provided to their primary carer to be
applied twice a day to both eyes for six weeks. The project team provided repeated health edu-
cation messages around hygiene and sanitation. The first round of MDA was administered to
all individuals in the three cohort villages immediately after time-point 3. No adverse effects
were reported.
C. trachomatis detection
Two protocols were used for both genomic DNA extraction and C. trachomatis detection. For
time-point 1 samples, genomic DNA was extracted from dry swabs using the PowerSoil DNA
isolation Kit (MO Bio Laboratories, California, USA) according to manufacturer’s instruc-
tions. For time-points 2 to 5, genomic DNA was extracted from samples stored in RNAlater
using the Norgen DNA/RNA Purification Kit (Norgen Biotek Corp, Canada) following the
manufacturer’s instructions.
C. trachomatis was detected in the time-point 1 samples using a droplet digital PCR assay
(ddPCR) and at time-points 2 to 5 using multiplex quantitative real-time PCR (qPCR) previ-
ously evaluated against ddPCR [17, 32, 33]. Both assays detect chlamydial plasmid open read-
ing frame 2 (pORF2), C. trachomatis outer membrane complex protein B (omcB) and human
endogenous control gene ribonuclease P/MRP Subunit P30 (RPP30) [33], using the same
primer and probe sequences. The ddPCR reaction contained 5μl of DNA template and prim-
ers/probes at a final concentration of 0.3nM using Taqman mastermix. PCR reaction condi-
tions were as follows: 95˚C for 10 minutes, then 40 cycles of 95˚C for 10 seconds and 60˚C for
30 seconds and finally 98˚C for 12 minutes. Droplets were then examined for fluorescence on
a QX200TM Droplet Reader (Bio-Rad, UK), providing a quantitative result. The qPCR assay
was performed on a ViiA7 thermal cycler (Thermo Fisher Scientific, Massachusetts, USA)
using TaqMan Multiplex Master mix in a final volume of 20 μl, containing 4μl of DNA tem-
plate and primers and probes each at a final concentration of 0.3nM. Cycling conditions were
as follows: 95˚C hold for 20 seconds followed by 40 cycles of 95˚C for 1 second and 60˚C for
20 seconds. Samples were tested in duplicate and were considered C. trachomatis positive if
either replicate amplified omcB and/or pORF2 with a cycle threshold (CT) value <40. In order
to compare agreement between ddPCR and qPCR assays, Norgen-extracted DNA from time-
point 2 samples (extracted from the first swab stored in RNAlater) were tested using both
methods and the results are shown in S1A Table.
Analysis of human gene expression
Total RNA was extracted from samples stored in RNAlater using the Norgen DNA/RNA Puri-
fication Kit (Norgen Biotek Corp, Canada) and reverse transcribed using the SuperScript
VILO cDNA Synthesis Kit (Life Technologies) following the manufacturer’s instructions. Rela-
tive abundance of host gene targets was quantified by real-time PCR using customized Taq-
Man Microfluidic 384-well Array Cards (Thermo Fisher Scientific, Massachusetts, USA) on a
ViiA7 real-time PCR machine (Thermo Fisher Scientific, Massachusetts, USA), as previously
described [17]. A total of 46 genes of interest were selected based on our previously reported
time-point 1 findings, in which we selected genes that were significantly associated with
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clinical signs and/or C. trachomatis infection status. HPRT1 was included to each PCR run as
an endogenous control gene.
Statistical analysis
Data were managed in Microsoft Access. The ΔCT method was used to adjust for the concen-
tration of input RNA by subtracting the cycle threshold (CT) value of each gene from the CT
value of HPRT1 in the same sample [34]. The distribution of ΔCT values were plotted to assess
normality. Host gene expression, C. trachomatis infection and clinical data were analysed in
STATA v14.
For each time-point the prevalence of clinical signs and C. trachomatis infection was esti-
mated and the association between infection and each of TF and TP was estimated using logis-
tic regression. The effect of MDA on infection, TF, TP and AT (Active Trachoma) was
estimated using a random effects logistic regression. Each of infection, TF, TP and AT were
used as the outcome variable in four separate regressions, the observations from the first three
time-points were compared with the observations from time-point 4 (the first observation
after the MDA) and participant ID was included as a random effect to account for the fact that
these were repeated observations within individuals. An identical analysis was repeated com-
paring the observations from time-point 5 to those from before MDA to assess whether the
estimated effect persisted at six months post treatment.
The change in mean ΔCT value from time-point 1 was plotted for 46 genes at each of the
four subsequent time-points and inspected to identify any clear differences between time-
points. The change in mean ΔCT following MDA was formally tested by comparing the mean
ΔCT in the first three time-points with that from the fourth time-point using a random effects
linear regression, with the ΔCT value of each gene as the outcome variable, whether an obser-
vation was before or after MDA as the exposure. Participant ID was included as a random
effect to again account for repeated observations of the same individuals. An interaction term
was included between before/after MDA and whether an individual was actually treated or not
to assess the evidence of whether gene expression response after MDA was different in the
treated and the untreated groups. These analyses were also repeated comparing the fifth time-
point with the three pre-MDA time-points to identify if the effect persisted. Gene expression
was then compared at time-point 4 only between treated and untreated individuals. These
analyses were initially performed unadjusted and then adjusted for infection status (clinical
signs were not adjusted for as they were likely to be caused by both infection and gene expres-
sion, rather than the other way around so adjusting for these could bias our estimates). The
Benjamini and Hochberg method was used to control for the false discovery rate of 5% [35].
Multivariable linear regression was used at each of the five time-points presented in this
report, to test the association of each gene’s expression with clinical signs and infection, adjust-
ing for age and sex and assuming a false discovery rate (FDR) of 5% in multiple comparisons
[35].
A Preferred Reporting Item (STROBE_checklist_cohort 2-12-18) is included in the sup-
porting information. Accession numbers for each gene included in this analysis are included
at the end of this manuscript. The protocols used in our analyses are accessible on protocols.io
website using the accession number https://dx.doi.org/10.17504/protocols.io.zyhf7t6
List of accession numbers for genes
HPRT1-Hs02800695, ALOX5-Hs01095330, CCL18-Hs00268113, CCL2-Hs00234140,
CCL20-Hs01011368, CD247-Hs00609515, NCAM1-Hs00941830, CDH1-Hs01023894,
CDH2-Hs00983056, CXCL13-Hs00757930, CXCL5-Hs01099660, DEFB4B;
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DEFB4A-Hs00175474, DUOX2-Hs00204187, FGF2-Hs00266645, IFNG-Hs00989291,
IL10-Hs00961622, IL12B-Hs01011518, IL17A-Hs00174383, IL19-Hs00604657,
IL1B-Hs01555410, IL21-Hs00222327, IL22-Hs01574154, IL23A-Hs00900828,
IL6-Hs00985639, IL8-Hs00174103, MMP12-Hs00899662, MMP7-Hs01042796,
MMP9-Hs00234579, MUC1-Hs00159357, MUC4-Hs00366414, MUC5AC-Hs00873651,
MUC7-Hs03047182, MZB1-Hs00414907, NCR1-Hs00183118, PDGFB-Hs00966522,
CD274-Hs01125301, S100A4-Hs00243202, S100A7-Hs01923188, SERPINB4;SER-
PINB3-Hs00741313, SOCS1-Hs00705164, SOCS3-Hs02330328, SPARCL1-Hs00949881,
TGFB1-Hs00998133, VIM-Hs00185584, CTGF-Hs00170014, PTGS2-Hs00153133,
Results
Study participants
At census we registered a total of 666 children aged between 6 and 10 years who were eligible
for recruitment at the beginning of this study from three trachoma-endemic villages. At time-
point one 506 participants were assessed; their demography, clinical signs and infection status
have previously reported in detail [17]. In general participants were predominantly from the
Maasai ethnic group (652/666, 97.9%) with a similar number of males (332, [49.9%]) and
females (334 [50.1%]) and a mean age of 7.01 years (SD 2.0) at the time of commencing the
study. At time-points 2, 3, 4, and 5 we assessed 537, 466, 467 and 477 children, respectively. At
each time-point some children were not examined due to being absent in the village, having
moved away or declining to participate. After time-point 1, the recruitment of new partici-
pants into the longitudinal study was permitted at the second time-point only. MDA was
offered immediately after time-point 3 to all members of the three cohort villages. The
reported community-wide coverage was 68.7%. All study participants examined in time-point
3 (466) were treated except one who refused. At time-point 4, 392/466 (84.1%) of the individu-
als seen had been treated.
Clinical signs of trachoma
At time-point 1 the clinical signs previously reported were based on grading of conjunctival
photographs, to enable subsequent comparison with the final time-point for determination of
scarring incidence and progression [17]. However, for consistency within this analysis of the
first five time-points, the field grading data was used. The agreement between field and photo-
graph grading for time-point 1 is shown in S1B Table. Kappa scores between field and photo-
graphs grading were 0.92 for TF and 0.68 for TP, with TP being slightly under-reported by
field graders.
The prevalence of TF in the first three time-points prior to MDA was fairly consistent (171/
506 [33.8%], 163/537 [30.2%] and 104/467 [22.3%]), dropping to 52/467 (11.1%) and 61/479
(12.6%) post-MDA at time-points 4 and 5 (Fig 1). The prevalence of TP was consistently lower
than TF and also dropped substantially following MDA (Fig 1). There were no statistically sig-
nificant differences between males and females in terms of the proportion showing signs of TF
and/or TP at any time-point (S2 Table), with the exception of time-point 1 where there was
possibly a weak association between TP and female sex.
C. trachomatis infection
The prevalence of infection was fairly consistent prior to MDA, dropping very slightly from
15.4% and 15.3% at time-points 1 and 2 to 11.6% at time-point 3. Three months after azithro-
mycin MDA (time-point 4) infection prevalence dropped to 1.3% and then increased slightly
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to 2.5% at time-point 5 (Fig 1). There was strong evidence for an association between C. tra-
chomatis infection and clinical signs (TF, TP) at all five time-points (Table 1), with the excep-
tion of TP at time-point 5. There was a significant reduction in TF, TP and C. trachomatis
detection in post-MDA time-points 4 and 5 relative to the combined odds at pre-MDA time-
points 1–3 (Table 2). The inflammatory disease (TF and/or TI (active trachoma)) and infection
status for each individual at each time-point is shown in Fig 2; participants were grouped by
infection and disease status at baseline. There were no statistically significant differences
between males and females in terms of the proportion testing positive for C. trachomatis at any
time-point (S2 Table).
Fig 1. The prevalence of C. trachomatis infection and clinical signs before and after MDA. At time-points 1, 2, 3, 4,
and 5 data are shown for 506, 537, 466, 467 and 477 children respectively.
https://doi.org/10.1371/journal.pntd.0007559.g001
Table 1. The association between C. trachomatis detection and clinical signs by time-point. Clinical signs are based on field grading from all five time-points.
Time-point Follicular Inflammation (TF) Papillary inflammation (TP)
No TF (%) TF (%) No TP (%) TP (%)
1
(n = 506)
Ct infected (%) 18/335 (5.4) 60/171 (35.1) 38/407 (9.3) 40/99 (40.4)
OR (95%CI) - 9.52 (5.4–16.8) - 6.58 (3.9–11.1)
p-value - <0.0001 - <0.0001
2
(n = 536)
Ct infected (%) 29/374 (7.8) 53/162 (32.7) 38/429 (8.9) 44/107 (41.1)
OR (95%CI) - 5.78 (3.5–9.5) - 7.19 (4.3–12.0)
p-value - <0.0001 - <0.0001
3
(n = 466)
Ct infected (%) 19/362 (5.3) 35/104 (33.7) 30/398 (7.5) 24/68 (35.3)
OR (95%CI) - 9.16 (4.9–16.9) - 6.69 (3.6–12.5)
p-value - <0.0001 - <0.0001
Azithromycin MDA
4
(n = 467)
Ct infected (%) 3/415 (0.7) 3/52 (5.8) 4/457 (0.9) 2/10 (20.0)
OR (95%CI) - 8.41 (1.7–42.8) - 28.31 (4.5–177.5)
p-value - 0.010 - <0.0001
5
(n = 477)
Ct infected (%) 4/417 (1.0) 8/60 (13.1) 10/442 (2.3) 2/35 (5.7)
OR (95%CI) - 15.88 (4.6–54.5) - 2.62 (0.6–12.4)
p-value - <0.0001 - 0.226
https://doi.org/10.1371/journal.pntd.0007559.t001
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Conjunctival gene expression
Forty-six genes of interest were quantified in all individuals who were sampled at each of the
five time-points. All amplified targets were included in the analyses. For each time-point, mul-
tivariate linear regression models were constructed for expression of each gene to investigate
associations with TF, TP and C. trachomatis infection, adjusting for age and sex (S3 Table).
The associations between the expression of specific genes with clinical signs and C. trachomatis
infection was similar at each time-point and was consistent with the baseline (time-point 1)
report [17]. Briefly, in individuals with C. trachomatis infection, IFNG, IL22, CCL2, IL12B,
CD274, IL21, IL17A and SOCS1 genes were consistently the most upregulated and S100A4,
ALOX5, MMP7, MUC5AC, MUC7, MUC4, MUC1, CDH2 and CDH1 genes were the most
downregulated. In individuals with TF and TP, S100A7, CCL18, MMP12, CXCL13, IL10, IL19,
IL21 and IL17A were the most upregulated while S100A4, SPARCL1, ALOX5 and MUC5AC
were the most downregulated.
For each target, the difference in mean gene expression (across all individuals) was calculated
at each time-point relative to the mean expression at time-point 1 (Fig 3). There was only mod-
est variability between these time-points, with the exception of time-point 4, three months after
MDA, which showed marked differences compared to time-point 1 (and the other time-points).
The largest increases in expression at time-point 4 relative to time-point 1 were found in
Table 2. Comparison of C. trachomatis infection and disease signs between the pre-treatment (odds of time-points 1, 2 and 3) to the post-treatment time-points (4
and 5 analysed separately). Clinical signs are based on field grading from all five time-points.
Infection TF TP Active Trachoma
Combined odds of pre-MDA time-points vs. time-point 4 (3 months post-MDA) OR 0.01 0.10 0.03 0.08
(95%CI) (0.004–0.04) (0.06–0.17) (0.01–0.07) (0.05–0.13)
p-value <0.0001 <0.0001 <0.0001 <0.0001
Combined odds of pre-MDA time-points vs. time-point 5 (6 months post-MDA) OR 0.04 0.15 0.18 0.14
(95%CI) (0.02–0.10) (0.10–0.23) (0.11–0.30) (0.10–0.22)
p-value <0.0001 <0.0001 <0.0001 <0.0001
https://doi.org/10.1371/journal.pntd.0007559.t002
Fig 2. The clinical disease (Active Trachoma) and infection status of individuals at each time-point, ordered by
status at baseline. Each row represents an individual and each column represents a time-point.
https://doi.org/10.1371/journal.pntd.0007559.g002
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SPARCL1, MUC5AC, CDH2, CTGF, NCAM1, CDH1, MUC7, S100A4, and IL12B (Fig 3). The
largest decreases were in S1007A, CCL18, CXCL5, DEFB4A, CXCL13, IL19, MMP12, IDO1,
IL1B, and IL17A (Fig 3). By time-point 5, six months after MDA, difference in mean gene
expression had mostly returned to levels that were similar to those prior to treatment (Fig 3).
The change in mean ΔCT for the expression of each gene from the three time-points before
MDA to the fourth time-point three months after MDA was estimated for all participants, and
also separately for both individuals who received MDA and those who did not, adjusting for
changes in C. trachomatis infection status (Table 3). This showed a significant change in mean
ΔCT of most targets from before MDA compared with three months after MDA. Interestingly,
this change was still observed in the untreated sub-group, albeit at a much reduced scale. The
changes in mean ΔCT were larger when the analysis was not adjusted for C. trachomatis infec-
tion (S4 Table).
To investigate the differences between the treated and untreated groups further, mean ΔCT
were compared between the groups at time-point 4 only (S5 Table). This revealed only subtle
differences in mean ΔCT between treated and untreated individuals. The anti-inflammatory
effect of MDA on gene expression was observed even in individuals without any detectable
episodes of chlamydial infection or clinical disease (F0, P0) at any of these five time-points (S6
Table).
Discussion
Infection
The prevalence of C. trachomatis was similar across the three time-points before MDA, sug-
gesting that the infection prevalence was relatively stable in this antibiotic-naïve community at
around 11% - 16%. The drop in the prevalence of infection and clinical signs at time-point 3
may have been due to medium term natural variation in the prevalence, as strains of Chla-
mydia trachomatis come and go, due to the introduction of public health education to the
communities by the field team or possibly due to the change in seasons. There was a
Fig 3. Variation in conjunctival gene expression. The difference in mean ΔCT value (across all individuals) for each
gene at time-points 2, 3, 4 and 5 is shown relative to time-point 1. Values are adjusted for C. trachomatis infection and
active trachoma and are ordered by difference in mean gene expression at Time-point 4.
https://doi.org/10.1371/journal.pntd.0007559.g003
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Table 3. Estimated Fold Changes (FC) with their respective p-values comparing the expression of each gene pre-MDA (time-points 1,2 and 3) and post-MDA
(time-point 4). A FC of>1 indicates increased expression of the gene after MDA. Column 1 includes all participants, columns 2 and 3 show the results stratified by
whether an individual actually received the treatment or not. The final column (p-value for interaction) assesses the evidence as to whether the fold change from before to
after MDA is different in the treated and untreated groups. Results are ordered by FC of ‘‘All” individuals (column 1).
Target All Untreated Only Treated Only p-value for interaction
FC p-value FC p-value FC p-value
SPARCL1 11.89 7.76 x10^-186 6.81 9.04 x10^-19 13.13 2.54 x10^-173 0.005
MUC5AC 4.02 3.95 x10^-145 2.89 1.20 x10^-14 4.26 5.35 x10^-136 0.009
CDH2 3.42 2.97 x10^-141 2.67 9.16 x10^-16 3.58 3.30 x10^-130 0.026
NCAM1 2.23 9.10 x10^-89 1.83 1.95 x10^-9 2.31 8.32 x10^-83 0.031
CTGF 2.20 3.57 x10^-96 2.25 1.27 x10^-17 2.20 4.10 x10^-81 0.818
MUC7 1.89 7.10 x10^-29 2.17 1.01 x10^-7 1.84 2.24 x10^-23 0.291
S100A4 1.82 7.83 x10^-79 1.75 1.56 x10^-12 1.83 5.50 x10^-69 0.612
CDH1 1.72 1.23 x10^-80 1.69 9.80 x10^-14 1.72 2.55 x10^-69 0.808
FGF2 1.50 2.86 x10^-9 1.48 0.019 1.50 4.19 x10^-8 0.934
SERPINB4 1.43 1.91 x10^-3 1.65 0.067 1.39 0.009 0.570
IL12B 1.42 5.47 x10^-15 1.49 4.10 x10^-4 1.41 1.97 x10^-12 0.657
TGFB1 1.34 2.53 x10^-45 1.43 4.80 x10^-12 1.33 6.55 x10^-36 0.178
ALOX5 1.29 7.49 x10^-39 1.37 7.71 x10^-11 1.27 1.24 x10^-30 0.133
MUC1 1.24 8.04 x10^-17 1.35 4.05 x10^-6 1.22 9.95 x10^-13 0.161
NCR1 1.23 2.51 x10^-10 1.25 0.007 1.23 7.76 x10^-9 0.835
PDGFB 1.22 7.96 x10^-14 1.35 1.26 x10^-5 1.20 2.59 x10^-10 0.130
GAPDH 1.20 5.05 x10^-11 1.49 1.68 x10^-8 1.16 1.33 x10^-6 0.001
SOCS1 1.20 2.64 x10^-8 1.49 5.69 x10^-7 1.15 6.66 x10^-5 0.003
MUC4 1.16 1.80 x10^-7 1.34 6.1 x10^-5 1.13 6.01 x10^-5 0.034
VIM 1.15 9.83 x10^-10 1.22 4.08 x10^-4 1.14 2.11 x10^-7 0.242
CD247 1.01 0.757 1.10 0.196 0.99 0.856 0.205
MMP9 0.95 0.242 0.98 0883 0.95 .0224 0.731
IFNG 0.95 0.219 0.93 0.521 0.95 0.293 0.860
MMP7 0.93 0.033 1.08 0.441 0.90 0.009 0.086
IL23A 0.88 5.88 x10^-4 1.00 0.989 0.86 1.73 x10^-4 0.127
IL22 0.83 0.020 1.26 0.232 0.76 0.002 0.016
IL6 0.83 5.24 x10^-4 0.83 0.150 0.83 0.001 0.959
CCL20 0.82 3.80 x10^-6 0.92 0.447 0.80 2.29 x10^-6 0.240
IL8 0.72 1.42 x10^-18 0.72 4.81 x10^-4 0.72 4.02 x10^-16 0.980
PTGS2 0.70 1.97 x10^-17 0.79 0.02.52 0.69 8.27 x10^-17 0.210
DUOX2 0.69 7.01 x10^-25 0.87 0.134 0.67 1.81 x10^-26 0.006
IL10 0.67 7.68 x10^-24 0.80 0.026 0.64 6.84 x10^-24 0.047
MZB1 0.65 3.20 x10^-17 0.71 0.008 0.64 6.23 x10^-16 0.466
CD274 0.63 6.37 x10^-37 0.77 0.004 0.61 1.28 x10^-36 0.018
CCL2 0.60 2.63 x10^-22 0.63 5.52 x10^-4 0.59 5.94 x10^-20 0.617
SOCS3 0.59 1.13 x10^-38 0.76 0.006 0.57 5.67 x10^-39 0.007
IL1B 0.52 1.78 x10^-43 0.61 2.81 x10^-5 0.50 1.55 x10^-40 0.140
IL21 0.51 3.18 x10^-24 0.72 0.044 0.48 1.03 x10^-24 0.022
IL17A 0.48 6.01 x10^-44 0.64 7.36 x10^-4 0.46 2.57 x10^-43 0.017
IDO1 0.44 6.25 x10^-90 0.68 1.69 x10^-4 0.41 4.74 x10^-93 9.55 x10^-6
MMP12 0.43 9.98 x10^-70 0.56 1.87 x10^-6 0.41 6.82 x10^-67 0.018
IL19 0.40 5.00 x10^-63 0.55 1.42 x10^-5 0.37 4.32 x10^-61 0.012
CXCL5 0.39 2.79 x10^-65 0.61 3.88 x10^-4 0.36 6.18 x10^-66 7.64 x10^-4
DEFB4A 0.38 1.32 x10^-64 0.52 1.16 x10^-5 0.36 1.94 x10^-62 0.015
(Continued)
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substantial reduction in infection prevalence at three months post-MDA, however, it rose
slightly by six months post-MDA, suggesting some limited re-emergence of infection. This
may be due to insufficient MDA coverage within the community, contact with individuals
from surrounding untreated communities, or failure to complete the 6-week daily treatment
course of tetracycline eye ointment for infants under 6 months. Members of these communi-
ties travel quite frequently to search for pastures and water for livestock, to visit markets and
for social interactions with other communities. As a result, it was difficult to achieve high
MDA coverage. Previous studies from Tanzania and The Gambia have also reported on the
importance of contact between communities as a risk factor for reinfection following treat-
ment [10, 11, 36].
Disease
Clinical signs of inflammation were strongly correlated with C. trachomatis infection at all five
time-points. In our previous systematic review and meta-analysis we found a strong correlation
between TF and C. trachomatis infection and a moderate correlation between intense papillary
inflammation (TI) and infection prior to initiation of MDA, however after treatment the corre-
lation was weaker for TF and no correlation was found for TI [14]. Most of these earlier studies
included multiple rounds of MDA and reported data several years after initiating treatment,
therefore it might be too early to see this trend in our cohort. There was no consistent difference
in the prevalence of clinical signs of inflammation between males and females, with the excep-
tion of the first timepoint which showed a non-significant trend of more TP in females.
Gene expression
Our findings in this study of the associations between host gene expression, C. trachomatis
infection and clinical signs of inflammation were consistent with previous reports from our-
selves and others [16, 18, 21, 22, 24, 37, 38]. Targets that were consistently associated with clini-
cal signs (TF/TP) at all five time-points included antimicrobial peptides (S100A7), pro-
inflammatory cytokines and chemokines (CCL18, CXCL13, IL10, IL19, IL21, IL17A), matrix
modifiers (MMP12 and SPARCL1), epithelial-mesenchymal transition markers (S100A4),
microbiota responses (ALOX5) and mucins (MUC5AC). Likewise, C. trachomatis infection was
consistently associated with pro-inflammatory cytokines and chemokines (IFNG, IL22, CCL2,
IL12B, IL21, IL17A), regulators/signalling pathways (SOCS1, CD274), S100A4, ALOX5, matrix
modifiers (MMP7, SPARCL1) and mucins (MUC7). We discussed the functions of these genes
and their potential roles in the clearance of C. trachomatis infection and immunopathology in
detail in our baseline paper [17]. The results at each of the subsequent time-points support the
data from baseline, suggesting that strong IFNG/IL12 responses are important in the clearance
of infection, whilst Th17 cell associated cytokines and matrix factors are associated with both
infection and the clinical inflammation which persists after infection has been cleared.
Large changes in gene expression were detected at time-point 4, three months after MDA
with azithromycin, relative to the three time-points prior to MDA. This variation in gene
Table 3. (Continued)
Target All Untreated Only Treated Only p-value for interaction
FC p-value FC p-value FC p-value
CXCL13 0.38 1.19 x10^-47 0.50 3.58 x10^-5 0.36 3.28 x10^-45 0.067
CCL18 0.33 8.10 x10^-49 0.47 5.75 x10^-5 0.31 7.95 x10^-47 0.032
S100A7 0.28 4.90 x10^-55 0.53 0.002 0.25 3.61 x10^-56 7.03 x10^-4
https://doi.org/10.1371/journal.pntd.0007559.t003
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expression largely returned to pre-MDA levels by time-point 5, six months post-MDA. Azithro-
mycin appeared to have an anti-inflammatory effect on gene expression, reversing the direction
of gene expression change usually associated with clinical signs and C. trachomatis infection.
Genes normally downregulated in individuals with C. trachomatis infection and/or inflamma-
tion were upregulated post-MDA (SPARCL1, MUC5AC, CDH2, CTGF, NCAM1, CDH1,
S100A4, MUC7, and FGF2), whilst genes normally upregulated (S100A7, CCL18, CXCL5,
CXCL13, IL19, IDO1, MMP12, IL17A, IL1B and IL21) were strongly downregulated post-MDA.
The effect was greatest when C. trachomatis infection was not adjusted for, however the effect
was still large after adjustment for infection, suggesting that azithromycin has an immunomod-
ulatory effect on gene expression that is independent of the concurrent reduction in infection.
This effect was also seen in individuals without any episodes of C. trachomatis infection and
clinical signs of inflammation across all 5 time-points, supporting this hypothesis. However, we
cannot exclude the possibility that azithromycin treatment reduced ocular infections with other
sub-clinical or mild inflammation-causing organisms in these individuals. Interestingly, a
change in mean gene expression post-MDA was also observed in individuals who did not
receive treatment. This could be due to a reduction in transmission and therefore exposure to
C. trachomatis and/or other infectious organisms within the community as a whole.
Azithromycin has previously been reported to have anti-inflammatory effects in humans,
animal and in vitro models, leading to improved clinical outcomes through a combined
approach of clearing infection and reducing pathological host inflammatory responses [39].
One pre-surgical dose of azithromycin reduced the level of pro-inflammatory cytokines and
chemokines detected in oral fluid 6 days following dental implant surgery relative to amoxicil-
lin [40]. Relative to other non-macrolide antibiotics, azithromycin reduced levels of IL-6, IL-8,
TNF-α and GM-CSF proteins in individuals with pneumonia and rhinovirus infections [41–
43]. MMP9 expression was reduced in the airways of lung transplanted individuals treated
with azithromycin between 3 and 6 months [44], and in an experimental laminectomy model
in rats, azithromycin was associated with reduction of fibrosis and inflammatory cell density
six weeks after administration [45]. Immunomodulatory effects of azithromycin are thought
to be enhanced by its long half-life in tissue, lasting for several weeks [46, 47]. In addition to
localised anti-inflammatory effects, one round of azithromycin, administered for trachoma
control, was associated with a large reduction in infectious and all-cause childhood mortality
[48]; a finding which was reinforced by a large multi-country placebo-controlled clinical trial
[49]. Our findings of an immunomodulatory effect of azithromycin are therefore consistent
with published evidence and suggest that MDA for trachoma control may have an additional
protective effect through a systemic reduction in inflammation.
This study has several limitations. It was only feasible to sample one eye from study partici-
pants, thus only the left eye was examined and sampled throughout the longitudinal study. The
age range of study participants was limited due to the study design of the overall longitudinal
study, which this investigation was nested within. The method of C. trachomatis detection was
changed after the first time-point, which could introduce inconsistencies between the infection
results of the first relative to later time-points. Agreement between the two methods used was
however deemed acceptable (S1A table). The infection loads of discrepant results were very low
and at around the limit of detection. Given the large sample size and the use of three pre-MDA
time-points, this variation is not expected to significantly alter the results or their interpretation.
Conclusions
We present evidence that one round of oral azithromycin treatment exerted a strong anti-
inflammatory effect on conjunctival gene expression, detectable three months following
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treatment but mostly returning to pre-MDA levels by six months. This effect was also observed
in individuals without C. trachomatis infection and clinical signs of inflammation across all
five time-points, indicating that the immunomodulatory effect was at least in part independent
of the reduction of C. trachomatis infection. Interestingly, a reduced effect was also seen in
individuals who did not receive treatment, which could reflect a community reduction in
infection transmission and exposure. A limitation of this study is that we cannot determine
whether this effect is mediated directly through inhibition of pro-inflammatory intracellular
signalling molecules, through reductions in concurrent, sub-clinical infections, and/or
through reduction of infection exposure, and future work should seek to understand these
mechanisms. Conjunctival papillary inflammation is a significant risk factor for scarring pro-
gression [2], therefore the anti-inflammatory effect of azithromycin might have therapeutic
potential in limiting the development of disease sequelae, that goes beyond its effect on the
prevalence of ocular C. trachomatis infection.
Supporting information
S1 Checklist. STROBE checklist.
(DOC)
S1 Table. Table A) 2 x 2 table showing agreement between qPCR and ddPCR assays for C. tra-
chomatis detection in DNA extracted from conjunctival swabs at time-point 2. Sensitiv-
ity = 82.6% (95% CI 72.8–89.9), Specificity = 96.7% (95% CI 96.7–99.4), NPV = 96.6% (95% CI
94.8–97.6%); PPV = 91.0% (95% CI 82.9–95.5%); Cohens Kappa = 0.84, Accuracy: overall
probability that a sample will be correctly classified 95.8% (95% CI 93.7–97.4), for these sam-
ples at this prevalence (16.4%) with ddPCR as the reference standard. Table B) Agreement
between field and photo grading at baseline (time-point 1) for follicular and papillary inflam-
mation in the conjunctiva. Kappa scores between field and photographs grading were 0.92 for
TF and 0.68 for TP.
(DOCX)
S2 Table. The relationship between sex and (i) clinical signs (from field grading) and (ii) C.
trachomatis infection of each of the 5 time-points. The number of individuals with each clini-
cal phenotype or infection is shown as a proportion of the total number of males and females
at each time-point. Associations between sex and clinical phenotypes or infection were tested
using logistic regression.
(DOCX)
S3 Table. Multivariable linear regression models for conjunctival gene expression associ-
ated with clinical signs, C. trachomatis, female sex and age. FC = fold change. Using the Ben-
jamini and Hochberg approach to adjust for multiple comparisons, in order to control the
false discovery rate<5% only tests with a p-value below 0.027 are considered statistically sig-
nificant.
(XLSX)
S4 Table. Estimated Fold Changes (FC) with their respective p-values comparing the
expression of each gene between the combined first three time-points (time-points 1, 2
and 3) before MDA and time-point 4 (three months after MDA), not adjusted for C. tra-
chomatis infection. A FC of>1 indicates increased expression of the gene at time-point 4.
Random effects multivariable linear regression of all individuals (first panel), untreated only
(second panel) and treated only (third panel). The final column (p-value for interaction) pro-
vides evidence as to whether the fold change from before to after MDA is different in the
Azithromycin Effect on Gene Expression
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007559 July 15, 2019 14 / 18
treated and untreated groups. Results are ordered by FC of ‘‘All” individuals. Benjamini and
Hochberg approach was used to adjust for multiple comparisons, in order to control the false
discovery rate<5%, only tests with a p-value <0.035 are considered statistically significant.
(DOCX)
S5 Table. Estimated Fold Change (FC) with their respective p-values for the expression of
each gene at time-point 4 only (three months post MDA), comparing MDA treated (after
time-point 3) to untreated individuals. Multivariable linear regression of all individuals
adjusted (first panel) and not adjusted (second panel) for C. trachomatis infection. Results are
ordered by FC of adjusted data with infection. Benjamini and Hochberg approach was used to
adjust for multiple comparisons, in order to control false discovery rate<5%, only tests with a
p-value <0.009 are considered statistically significant.
(DOCX)
S6 Table. Estimated fold changes (FC) with their respective p-values comparing the expres-
sion of each gene between the combined first three time-points (1, 2 and 3) before MDA
and separately time-points 4 and 5 (three and six months following MDA treatment), in
122 individuals who were free from infection and disease (F0, P0) at all 5 time-points.
Results are ordered by Fold Change (FC) in pre-MDA time-points vs. time-point 4. Benjamini
and Hochberg approach was used to adjust for multiple comparisons, in order to control the
false discovery rate<5%, only tests with a p-value <0.035 are considered statistically signifi-
cant.
(DOCX)
Author Contributions
Conceptualization: Robin L. Bailey, David C. W. Mabey, Martin J. Holland, Matthew J.
Burton.
Data curation: Athumani M. Ramadhani, Tamsyn Derrick, David Macleod.
Formal analysis: Athumani M. Ramadhani, Tamsyn Derrick, David Macleod.
Funding acquisition: Martin J. Holland, Matthew J. Burton.
Investigation: Athumani M. Ramadhani, Tamsyn Derrick, Martin J. Holland, Matthew J.
Burton.
Methodology: Athumani M. Ramadhani, Tamsyn Derrick, David Macleod, Patrick Massae,
Aiweda Malisa, Kelvin Mbuya, Chrissy H. Roberts, Martin J. Holland, Matthew J. Burton.
Project administration: Athumani M. Ramadhani, Patrick Massae, Aiweda Malisa, Kelvin
Mbuya, Tara Mtuy, William Makupa, Martin J. Holland, Matthew J. Burton.
Resources: Patrick Massae, Aiweda Malisa, Tara Mtuy, William Makupa, Martin J. Holland,
Matthew J. Burton.
Supervision: Martin J. Holland, Matthew J. Burton.
Visualization: David Macleod.
Writing – original draft: Athumani M. Ramadhani.
Writing – review & editing: Athumani M. Ramadhani, Tamsyn Derrick, David Macleod,
Tara Mtuy, William Makupa, Chrissy H. Roberts, Robin L. Bailey, David C. W. Mabey,
Martin J. Holland, Matthew J. Burton.
Azithromycin Effect on Gene Expression
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007559 July 15, 2019 15 / 18
References
1. Eliminating Trachoma: Accelerating Towards 2020. WHO, 2016, WHO Alliance for the Global Elimina-
tion of Trachoma by 2020: Geneva.
2. Ramadhani A.M., et al., Blinding Trachoma: Systematic Review of Rates and Risk Factors for Progres-
sive Disease. PLoS Negl Trop Dis, 2016. 10(8): p. e0004859. https://doi.org/10.1371/journal.pntd.
0004859 PMID: 27483002
3. WHO Alliance for the Global Elimination of Trachoma by 2020: progress report on elimination of tra-
choma, 2014–2016. Wkly Epidemiol Rec, WHO, 2017. 92(26): p. 359–68.
4. WHO, Weekly Epidemiological Record. WHO, 2018. 93(26): p. 12.
5. Flueckiger, R.M., et al., The global burden of trichiasis in 2016. bioRxiv, 2018.
6. WHO, Global elimination of blinding trachoma. Resolution WHA 51.11. Adopted by the World Health
Assembly 16 May 1998. 1998.
7. WHO, Report of the Eighth Meeting of the W.H.O. Alliance for the Global Elimination of Blinding Tra-
choma. Geneva, Switzerland: World Health Organization. WHO/PBD/GET/04.2 WHO/PBD/GET/04.2.,
2004.
8. Pant B.P., et al., Control of Trachoma from Achham District, Nepal: A Cross-Sectional Study from the
Nepal National Trachoma Program. PLoS Negl Trop Dis, 2016. 10(2): p. e0004462. https://doi.org/10.
1371/journal.pntd.0004462 PMID: 26871898
9. Solomon A.W., et al., Two doses of azithromycin to eliminate trachoma in a Tanzanian community. N.
Engl.J Med., 2008. 358(17): p. 1870–1871. https://doi.org/10.1056/NEJMc0706263 PMID: 18434662
10. Burton M.J., et al., Profound and sustained reduction in Chlamydia trachomatis in The Gambia: a five-
year longitudinal study of trachoma endemic communities. PLoS Negl Trop Dis, 2010. 4(10): p. e835.
https://doi.org/10.1371/journal.pntd.0000835 PMID: 20957147
11. Burton M.J., et al., Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of
a trachoma-endemic Gambian community: a longitudinal study. Lancet., 2005. 365(9467): p. 1321–
1328. https://doi.org/10.1016/S0140-6736(05)61029-X PMID: 15823382
12. Melese M., et al., Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic
treatments. JAMA, 2004. 292(6): p. 721–5. https://doi.org/10.1001/jama.292.6.721 PMID: 15304470
13. Grassly N.C., et al., The natural history of trachoma infection and disease in a gambian cohort with fre-
quent follow-up. PLoS.Negl.Trop.Dis., 2008. 2(12): p. e341. https://doi.org/10.1371/journal.pntd.
0000341 PMID: 19048024
14. Ramadhani A.M., et al., The Relationship between Active Trachoma and Ocular Chlamydia trachomatis
Infection before and after Mass Antibiotic Treatment. PLoS Negl Trop Dis, 2016. 10(10): p. e0005080.
https://doi.org/10.1371/journal.pntd.0005080 PMID: 27783678
15. Bailey R., et al., The duration of human ocular Chlamydia trachomatis infection is age dependent. Epide-
miol.Infect., 1999. 123(3): p. 479–486. https://doi.org/10.1017/s0950268899003076 PMID: 10694161
16. Faal N., et al., Temporal cytokine gene expression patterns in subjects with trachoma identify distinct
conjunctival responses associated with infection. Clin.Exp.Immunol., 2005. 142(2): p. 347–353. https://
doi.org/10.1111/j.1365-2249.2005.02917.x PMID: 16232223
17. Ramadhani A.M., et al., Immunofibrogenic Gene Expression Patterns in Tanzanian Children with Ocu-
lar Chlamydia trachomatis Infection, Active Trachoma and Scarring: Baseline Results of a 4-Year Longi-
tudinal Study. Frontiers in Cellular and Infection Microbiology, 2017. 7: p. 406. https://doi.org/10.3389/
fcimb.2017.00406 PMID: 28966918
18. Burton M.J., et al., Pathogenesis of progressive scarring trachoma in Ethiopia and Tanzania and its
implications for disease control: two cohort studies. PLoS Negl Trop Dis, 2015. 9(5): p. e0003763.
https://doi.org/10.1371/journal.pntd.0003763 PMID: 25970613
19. Hu V.H., et al., Innate immune responses and modified extracellular matrix regulation characterize bac-
terial infection and cellular/connective tissue changes in scarring trachoma. Infect Immun, 2012. 80(1):
p. 121–30. https://doi.org/10.1128/IAI.05965-11 PMID: 22038912
20. Burton M.J., et al., Post-operative recurrent trachomatous trichiasis is associated with increased con-
junctival expression of S100A7 (psoriasin). PLoS Negl Trop Dis, 2012. 6(12): p. e1985. https://doi.org/
10.1371/journal.pntd.0001985 Epub 2012 Dec 20. PMID: 23285311
21. Burton M.J., et al., Cytokine and fibrogenic gene expression in the conjunctivas of subjects from a Gam-
bian community where trachoma is endemic. Infect.Immun., 2004. 72(12): p. 7352–7356. https://doi.
org/10.1128/IAI.72.12.7352-7356.2004 PMID: 15557667
22. Burton M.J., et al., Active trachoma is associated with increased conjunctival expression of IL17A and
profibrotic cytokines. Infect Immun., 2011. 79(12): p. 4977–83. https://doi.org/10.1128/IAI.05718-11
Epub 2011 Sep 12. PMID: 21911461
Azithromycin Effect on Gene Expression
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007559 July 15, 2019 16 / 18
23. Faal N., et al., Conjunctival FOXP3 expression in trachoma: do regulatory T cells have a role in human
ocular Chlamydia trachomatis infection? PLoS.Med., 2006. 3(8): p. e266. https://doi.org/10.1371/
journal.pmed.0030266 PMID: 16881731
24. Bobo L., et al., Evidence for a predominant proinflammatory conjunctival cytokine response in individu-
als with trachoma. Infect.Immun., 1996. 64(8): p. 3273–3279. PMID: 8757864
25. Stellari F.F., et al., Azithromycin inhibits nuclear factor-kappaB activation during lung inflammation: an
in vivo imaging study. Pharmacol Res Perspect, 2014. 2(5): p. e00058. https://doi.org/10.1002/prp2.58
PMID: 25505605
26. Ratzinger F., et al., Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR
activity. Sci Rep, 2014. 4: p. 7438. https://doi.org/10.1038/srep07438 PMID: 25500904
27. Murphy B.S., et al., Azithromycin alters macrophage phenotype. J Antimicrob Chemother, 2008. 61(3):
p. 554–60. https://doi.org/10.1093/jac/dkn007 PMID: 18230686
28. Poachanukoon O., et al., Macrolides attenuate phorbol ester-induced tumor necrosis factor-alpha and
mucin production from human airway epithelial cells. Pharmacology, 2014. 93(1–2): p. 92–9. https://
doi.org/10.1159/000358366 PMID: 24556631
29. Giamarellos-Bourboulis E.J., Macrolides beyond the conventional antimicrobials: a class of potent
immunomodulators. Int J Antimicrob Agents, 2008. 31(1): p. 12–20. https://doi.org/10.1016/j.
ijantimicag.2007.08.001 PMID: 17935949
30. Dawson C.R., Jones B.R., and Tarizzo M.L., Guide to Trachoma Control. 1981, Geneva: World Health
Organization.
31. Thylefors B., et al., A simple system for the assessment of trachoma and its complications. Bull.World
Health Organ., 1987. 65(4): p. 477–483. PMID: 3500800
32. Roberts C.H., et al., Development and evaluation of a next-generation digital PCR diagnostic assay for
ocular Chlamydia trachomatis infections. J Clin Microbiol, 2013. 51(7): p. 2195–203. https://doi.org/10.
1128/JCM.00622-13 PMID: 23637300
33. Butcher R., et al., Reduced-cost Chlamydia trachomatis-specific multiplex real-time PCR diagnostic
assay evaluated for ocular swabs and use by trachoma research programmes. J Microbiol Methods,
2017.
34. Livak K.J. and Schmittgen T.D., Analysis of relative gene expression data using real-time quantitative
PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001. 25(4): p. 402–8. https://doi.org/10.1006/
meth.2001.1262 PMID: 11846609
35. Benjamini Y. and Hochberg Y., Controlling the False Discovery Rate:a Practical and Powerful Approach
to Multiple Testing. J R.Statistics Soc., 1995. 57: p. 289–300.
36. West S.K., et al., Risk of Infection with Chlamydia trachomatis from Migrants to Communities Undergo-
ing Mass Drug Administration for Trachoma Control. Ophthalmic Epidemiol, 2015. 22(3): p. 170–5.
https://doi.org/10.3109/09286586.2015.1010687 PMID: 26158574
37. bu El-Asrar A.M., et al., Expression of growth factors in the conjunctiva from patients with active tra-
choma. Eye., 2006. 20(3): p. 362–369. https://doi.org/10.1038/sj.eye.6701884 PMID: 15818386
38. Skwor T.A., et al., Role of secreted conjunctival mucosal cytokine and chemokine proteins in different
stages of trachomatous disease. PLoS.Negl.Trop.Dis., 2008. 2(7): p. e264. https://doi.org/10.1371/
journal.pntd.0000264 PMID: 18628987
39. Amsden G.W., Anti-inflammatory effects of macrolides—an underappreciated benefit in the treatment
of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J
Antimicrob Chemother, 2005. 55(1): p. 10–21. https://doi.org/10.1093/jac/dkh519 PMID: 15590715
40. Escalante M.G., et al., Comparison of Azithromycin and Amoxicillin Prior to Dental Implant Placement:
An Exploratory Study of Bioavailability and Resolution of Postoperative Inflammation. Journal of peri-
odontology, 2015. 86(11): p. 1190–1200. https://doi.org/10.1902/jop.2015.150024 PMID: 26252749
41. Lorenzo M.-J., et al., Lung inflammatory pattern and antibiotic treatment in pneumonia. Respiratory
Research, 2015. 16(1): p. 15.
42. Gielen V., Johnston S.L., and Edwards M.R., Azithromycin induces anti-viral responses in bronchial epi-
thelial cells. Eur Respir J, 2010. 36(3): p. 646–54. https://doi.org/10.1183/09031936.00095809 PMID:
20150207
43. Murphy D.M., et al., Azithromycin attenuates effects of lipopolysaccharide on lung allograft bronchial
epithelial cells. J Heart Lung Transplant, 2008. 27(11): p. 1210–6. https://doi.org/10.1016/j.healun.
2008.07.026 PMID: 18971093
44. Verleden S.E., et al., Azithromycin decreases MMP-9 expression in the airways of lung transplant recip-
ients. Transpl Immunol, 2011. 25(2–3): p. 159–62. https://doi.org/10.1016/j.trim.2011.06.006 PMID:
21740970
Azithromycin Effect on Gene Expression
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007559 July 15, 2019 17 / 18
45. Emmez H., et al., Immunomodulatory effectiveness of azithromycin in prevention of postlaminectomy
epidural fibrosis. Neurological Research, 2011. 33(4): p. 344–348. https://doi.org/10.1179/
016164110X12767786356471 PMID: 20810030
46. Langtry H.D. and Balfour J.A., Azithromycin. A review of its use in paediatric infectious diseases. Drugs,
1998. 56(2): p. 273–97. https://doi.org/10.2165/00003495-199856020-00014 PMID: 9711451
47. Leach A.J., et al., A prospective study of the impact of community-based azithromycin treatment of tra-
choma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis, 1997. 24(3): p. 356–
62. https://doi.org/10.1093/clinids/24.3.356 PMID: 9114185
48. Keenan J.D., et al., Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clin
Infect Dis, 2011. 52(7): p. 883–8. https://doi.org/10.1093/cid/cir069 PMID: 21427395
49. Keenan J.D., et al., Mass azithromycin distribution for reducing childhood mortality in sub-Saharan
Africa. The New England Journal of Medicine, 2018: p. https://doi.org/10.1056/NEJMoa1715474
Azithromycin Effect on Gene Expression
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007559 July 15, 2019 18 / 18
